首页 > 最新文献

Journal of geriatric oncology最新文献

英文 中文
Geriatric prehabilitation prior to surgery for kidney tumors: Study protocol for Pre-KiT - A randomized controlled trial 肾脏肿瘤手术前的老年康复:Pre-KiT的研究方案-一项随机对照试验。
IF 2.7 3区 医学 Q3 GERIATRICS & GERONTOLOGY Pub Date : 2026-01-26 DOI: 10.1016/j.jgo.2026.102893
Marie Juul-Haslund , Cecilia M. Lund , Troels G. Dolin , Katrine Schou-Jensen , Peter B. Østergren , Anders Vinther , Frederik F. Thomsen , Mikkel Fode

Introduction

Renal cell carcinoma (RCC) primarily affects older adults who often present with frailty, increasing their risk of surgical complications and delayed recovery. Prehabilitation, incorporating exercise, nutrition, and psychological support, may improve postoperative outcomes. However, no studies have investigated prehabilitation prior to surgery for RCC. The aim is to assess whether a one-month multimodal prehabilitation program including geriatric interventions improves recovery in patients with frailty undergoing surgery for localized RCC ≤ 7 cm.

Materials and methods

60 patients, aged ≥65, with a Clinical Frailty Scale (CFS) score of 3–6 are randomized 1:1 to standard care or prehabilitation involving home-based exercise, geriatric assessment with tailored interventions, and smoking cessation support. The primary outcome is change in Quality of Recovery-15 (QoR-15) 21 days postoperatively. Secondary outcomes include changes in QoR-15, health-related quality of life (EQ-5D-5L) and physical performance (30-s chair-stand test, handgrip strength) assessed preoperatively, 1, 21 and 90 days postoperatively. Postoperative complications will be evaluated using the Clavien-Dindo classification, alongside a cost-effectiveness analysis. Long-term outcomes include 1- and 5-year recurrence-free, cancer-specific, and overall survival.

Discussion

Pre-KiT explores if a pragmatic geriatric prehabilitation strategy is effective and feasible for older frail patients with RCC. The intervention is designed for easy implementation in clinical practice: administered by a single healthcare professional, requiring only one additional hospital visit, and consists of home-based exercises. This low-resource approach also aims to minimize financial costs, which is of importance for implementation possibilities. If successful, it could improve standard care and outcomes after surgery.
Trial registration: ClinicalTrials.gov ID: NCT06745609. Prospectively registered December 12th, 2024.
肾细胞癌(RCC)主要影响老年人,他们经常表现出虚弱,增加了手术并发症和延迟恢复的风险。康复训练,包括运动、营养和心理支持,可以改善术后预后。然而,没有研究调查RCC手术前的康复。目的是评估包括老年干预在内的为期一个月的多模式康复计划是否能改善因局限性RCC≤7 cm而接受手术的虚弱患者的康复。材料和方法:60例年龄≥65岁,临床虚弱量表(CFS)评分为3-6分的患者,以1:1的比例随机分为标准治疗或康复治疗,包括基于家庭的锻炼、定制干预的老年评估和戒烟支持。主要观察指标为术后21天恢复质量-15 (QoR-15)的变化。次要结局包括术前、术后1、21和90天评估的QoR-15、健康相关生活质量(EQ-5D-5L)和身体表现(30秒椅架测试、握力)的变化。术后并发症将使用Clavien-Dindo分类进行评估,并进行成本-效果分析。长期预后包括1年和5年无复发、癌症特异性和总生存期。讨论:Pre-KiT探讨了一种实用的老年康复策略对患有肾细胞癌的老年体弱患者是否有效和可行。该干预措施旨在便于在临床实践中实施:由一名保健专业人员管理,只需要一次额外的医院就诊,并包括以家庭为基础的练习。这种低资源方法还旨在尽量减少财政成本,这对执行的可能性很重要。如果成功,它可以改善手术后的标准护理和结果。试验注册:ClinicalTrials.gov ID: NCT06745609。预计于2024年12月12日注册。
{"title":"Geriatric prehabilitation prior to surgery for kidney tumors: Study protocol for Pre-KiT - A randomized controlled trial","authors":"Marie Juul-Haslund ,&nbsp;Cecilia M. Lund ,&nbsp;Troels G. Dolin ,&nbsp;Katrine Schou-Jensen ,&nbsp;Peter B. Østergren ,&nbsp;Anders Vinther ,&nbsp;Frederik F. Thomsen ,&nbsp;Mikkel Fode","doi":"10.1016/j.jgo.2026.102893","DOIUrl":"10.1016/j.jgo.2026.102893","url":null,"abstract":"<div><h3>Introduction</h3><div>Renal cell carcinoma (RCC) primarily affects older adults who often present with frailty, increasing their risk of surgical complications and delayed recovery. Prehabilitation, incorporating exercise, nutrition, and psychological support, may improve postoperative outcomes. However, no studies have investigated prehabilitation prior to surgery for RCC. The aim is to assess whether a one-month multimodal prehabilitation program including geriatric interventions improves recovery in patients with frailty undergoing surgery for localized RCC ≤ 7 cm.</div></div><div><h3>Materials and methods</h3><div>60 patients, aged ≥65, with a Clinical Frailty Scale (CFS) score of 3–6 are randomized 1:1 to standard care or prehabilitation involving home-based exercise, geriatric assessment with tailored interventions, and smoking cessation support. The primary outcome is change in Quality of Recovery-15 (QoR-15) 21 days postoperatively. Secondary outcomes include changes in QoR-15, health-related quality of life (EQ-5D-5L) and physical performance (30-s chair-stand test, handgrip strength) assessed preoperatively, 1, 21 and 90 days postoperatively. Postoperative complications will be evaluated using the Clavien-Dindo classification, alongside a cost-effectiveness analysis. Long-term outcomes include 1- and 5-year recurrence-free, cancer-specific, and overall survival.</div></div><div><h3>Discussion</h3><div>Pre-KiT explores if a pragmatic geriatric prehabilitation strategy is effective and feasible for older frail patients with RCC. The intervention is designed for easy implementation in clinical practice: administered by a single healthcare professional, requiring only one additional hospital visit, and consists of home-based exercises. This low-resource approach also aims to minimize financial costs, which is of importance for implementation possibilities. If successful, it could improve standard care and outcomes after surgery.</div><div><em>Trial registration</em>: <span><span>ClinicalTrials.gov</span><svg><path></path></svg></span> ID: <span><span>NCT06745609</span><svg><path></path></svg></span>. Prospectively registered December 12th, 2024.</div></div>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"17 2","pages":"Article 102893"},"PeriodicalIF":2.7,"publicationDate":"2026-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146064167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Response to letter to the Editor: Geriatric assessment and sarcopenia in pancreatic cancer: Toward personalized treatment beyond chronological age 胰腺癌的老年评估和肌肉减少症:超越实足年龄的个性化治疗。
IF 2.7 3区 医学 Q3 GERIATRICS & GERONTOLOGY Pub Date : 2026-01-26 DOI: 10.1016/j.jgo.2026.102890
Giovanni Trovato , Lisa Salvatore , Giampaolo Tortora
{"title":"Response to letter to the Editor: Geriatric assessment and sarcopenia in pancreatic cancer: Toward personalized treatment beyond chronological age","authors":"Giovanni Trovato ,&nbsp;Lisa Salvatore ,&nbsp;Giampaolo Tortora","doi":"10.1016/j.jgo.2026.102890","DOIUrl":"10.1016/j.jgo.2026.102890","url":null,"abstract":"","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"17 2","pages":"Article 102890"},"PeriodicalIF":2.7,"publicationDate":"2026-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146064147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A literature review on hypothalamic–pituitary–adrenal (HPA) axis dysregulation in older adults with cancer: A missing link in predicting treatment toxicity? 关于老年癌症患者下丘脑-垂体-肾上腺(HPA)轴失调的文献综述:预测治疗毒性的缺失环节?
IF 2.7 3区 医学 Q3 GERIATRICS & GERONTOLOGY Pub Date : 2026-01-24 DOI: 10.1016/j.jgo.2026.102854
Len De Nys
Older adults with cancer face disproportionately high rates of severe treatment-related toxicities, yet current prediction tools rarely incorporate biomarkers that capture physiological resilience. The hypothalamic–pituitary–adrenal (HPA) axis—central to stress adaptation, immune regulation, and tissue repair—undergoes pronounced age-related alterations, including elevated basal cortisol, reduced dehydroepiandrosterone (DHEA) and its sulphate form DHEAS, and an increased cortisol:DHEA(S) ratio. These changes may impair immune function, delay recovery, and exacerbate vulnerability to treatment toxicity. This narrative review synthesizes mechanistic and clinical evidence linking HPA-axis dysregulation to treatment tolerance in geriatric oncology. Common patterns include blunted diurnal cortisol slopes, elevated evening cortisol, and low DHEA(S), which are associated with fatigue, functional decline, and reduced survival across cancer types. However, their predictive value for acute treatment toxicities remains underexplored due to methodological heterogeneity, lack of age-specific reference ranges, and absence from existing geriatric toxicity models. This review proposes a translational roadmap that prioritizes (1) standardization of salivary cortisol/DHEA(S) protocols; (2) prospective, age-stratified validation studies using standardized toxicity endpoints; (3) interventional testing of behavioral or pharmacological strategies to modulate HPA function; and (4) integration into oncology workflows and electronic decision-support tools. Incorporating endocrine biomarkers into risk prediction could refine treatment stratification, enable targeted supportive care, and ultimately improve outcomes for older patients with cancer.
患有癌症的老年人面临着不成比例的高比例的严重治疗相关毒性,但目前的预测工具很少纳入捕捉生理弹性的生物标志物。下丘脑-垂体-肾上腺(HPA)轴-应激适应、免疫调节和组织修复的中心-经历明显的年龄相关改变,包括基础皮质醇升高,脱氢表雄酮(DHEA)及其硫酸盐形式DHEAS减少,皮质醇:DHEA(S)比率增加。这些变化可能损害免疫功能,延缓恢复,并加剧对治疗毒性的易感性。这篇叙述性综述综合了hpa轴失调与老年肿瘤治疗耐受性之间的机制和临床证据。常见的模式包括昼夜皮质醇斜率变钝、夜间皮质醇升高和低脱氢表雄酮(S),这与疲劳、功能下降和癌症类型的生存率降低有关。然而,由于方法学的异质性,缺乏年龄特异性参考范围,以及缺乏现有的老年毒性模型,它们对急性治疗毒性的预测价值仍未得到充分探讨。本综述提出了一个翻译路线图,优先考虑(1)唾液皮质醇/脱氢表雄酮(S)协议的标准化;(2)使用标准化毒性终点的前瞻性年龄分层验证研究;(3)干预测试调节HPA功能的行为或药物策略;(4)整合肿瘤学工作流程和电子决策支持工具。将内分泌生物标志物纳入风险预测可以细化治疗分层,实现有针对性的支持性护理,并最终改善老年癌症患者的预后。
{"title":"A literature review on hypothalamic–pituitary–adrenal (HPA) axis dysregulation in older adults with cancer: A missing link in predicting treatment toxicity?","authors":"Len De Nys","doi":"10.1016/j.jgo.2026.102854","DOIUrl":"10.1016/j.jgo.2026.102854","url":null,"abstract":"<div><div>Older adults with cancer face disproportionately high rates of severe treatment-related toxicities, yet current prediction tools rarely incorporate biomarkers that capture physiological resilience. The hypothalamic–pituitary–adrenal (HPA) axis—central to stress adaptation, immune regulation, and tissue repair—undergoes pronounced age-related alterations, including elevated basal cortisol, reduced dehydroepiandrosterone (DHEA) and its sulphate form DHEAS, and an increased cortisol:DHEA(S) ratio. These changes may impair immune function, delay recovery, and exacerbate vulnerability to treatment toxicity. This narrative review synthesizes mechanistic and clinical evidence linking HPA-axis dysregulation to treatment tolerance in geriatric oncology. Common patterns include blunted diurnal cortisol slopes, elevated evening cortisol, and low DHEA(S), which are associated with fatigue, functional decline, and reduced survival across cancer types. However, their predictive value for acute treatment toxicities remains underexplored due to methodological heterogeneity, lack of age-specific reference ranges, and absence from existing geriatric toxicity models. This review proposes a translational roadmap that prioritizes (1) standardization of salivary cortisol/DHEA(S) protocols; (2) prospective, age-stratified validation studies using standardized toxicity endpoints; (3) interventional testing of behavioral or pharmacological strategies to modulate HPA function; and (4) integration into oncology workflows and electronic decision-support tools. Incorporating endocrine biomarkers into risk prediction could refine treatment stratification, enable targeted supportive care, and ultimately improve outcomes for older patients with cancer.</div></div>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"17 2","pages":"Article 102854"},"PeriodicalIF":2.7,"publicationDate":"2026-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146046851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
What nutritional interventions can effectively treat sarcopenia in older adults with cancer? A systematic review 哪些营养干预措施可以有效治疗老年癌症患者的肌肉减少症?系统回顾。
IF 2.7 3区 医学 Q3 GERIATRICS & GERONTOLOGY Pub Date : 2026-01-20 DOI: 10.1016/j.jgo.2026.102850
Megan Pattwell , Michelle Gibbs , Colm Mac Eochagáin , Emma Crewe , Anne Barrell , Erin Stella Sullivan , Hannah Furness , Ione de Brito-Ashurst , Susanne Cruickshank , Nicolò Matteo Luca Battisti

Introduction

Cancer primarily affects older adults, with a significant proportion also experiencing sarcopenia which is associated with poor clinical outcomes. In older adults with cancer, sarcopenia is not only age-related but also exacerbated by disease processes, inflammation, and the catabolic effects of treatments such as chemotherapy and radiotherapy. Its presence is linked to increased treatment toxicity, longer hospitalisations, reduced physical function, and poorer survival rates. However, diagnosing sarcopenia remains challenging due to inconsistent criteria and limited access to diagnostic tools. Emerging evidence suggests that nutritional interventions may help prevent or reverse sarcopenia. This review aims to evaluate the effectiveness of nutritional interventions in managing sarcopenia in older adults with cancer.

Materials and methods

A systematic review was conducted using the PICO framework, targeting studies involving patients aged 65 and older with cancer and confirmed or likely sarcopenia. A total of 1439 studies were retrieved from databases and screened using Rayyan. Data extraction focused on outcomes related to body composition, physical performance, and nutritional intake. Risk of bias was assessed using RoB2, ROBINS-I, and ROBINS-E tools. Due to heterogeneity in study designs and outcome measures, a narrative synthesis was performed using SWiM guidelines. Studies were grouped by design and intervention type, and the GRADE approach was applied to assess evidence certainty.

Results

Nine studies (2016–2024) met the inclusion criteria. Interventions included dietary supplements, nutritional counselling, enteral feeding, and multimodal strategies. Most studies showed improvements in sarcopenia-related outcomes. Protein supplementation notably improved lean body mass and skeletal muscle index in some randomised control trials (RCTs). Observational studies found associations between certain dietary patterns—such as high fish and fat intake—and reduced sarcopenia risk.

Discussion

Nutritional interventions show promise in managing sarcopenia among older adults with cancer. However, further large-scale, standardised research is needed. Meanwhile, promoting good nutrition and physical activity remains essential.
导读:癌症主要影响老年人,其中很大一部分还经历了肌肉减少症,这与不良的临床结果有关。在老年癌症患者中,肌肉减少症不仅与年龄有关,而且还因疾病进程、炎症和化疗和放疗等治疗的分解代谢作用而加剧。它的存在与治疗毒性增加、住院时间延长、身体功能下降和生存率降低有关。然而,由于标准不一致和诊断工具有限,诊断肌肉减少症仍然具有挑战性。新出现的证据表明,营养干预可能有助于预防或逆转肌肉减少症。本综述旨在评估营养干预在老年癌症患者肌肉减少症治疗中的有效性。材料和方法:使用PICO框架进行系统综述,针对65岁及以上的癌症患者并确诊或可能患有肌肉减少症的研究。从数据库中检索到1439项研究,并使用Rayyan进行筛选。数据提取的重点是与身体成分、身体表现和营养摄入相关的结果。使用RoB2、ROBINS-I和ROBINS-E工具评估偏倚风险。由于研究设计和结果测量的异质性,使用SWiM指南进行叙事综合。研究按设计和干预类型分组,并采用GRADE方法评估证据确定性。结果:9项研究(2016-2024)符合纳入标准。干预措施包括膳食补充剂、营养咨询、肠内喂养和多模式策略。大多数研究显示肌肉减少症相关的结果有所改善。在一些随机对照试验(rct)中,补充蛋白质可显著改善瘦体重和骨骼肌指数。观察性研究发现,某些饮食模式(如大量摄入鱼类和脂肪)与降低肌肉减少症风险之间存在关联。讨论:营养干预在治疗老年癌症患者的肌肉减少症中显示出希望。然而,还需要进一步的大规模标准化研究。与此同时,促进良好的营养和身体活动仍然至关重要。
{"title":"What nutritional interventions can effectively treat sarcopenia in older adults with cancer? A systematic review","authors":"Megan Pattwell ,&nbsp;Michelle Gibbs ,&nbsp;Colm Mac Eochagáin ,&nbsp;Emma Crewe ,&nbsp;Anne Barrell ,&nbsp;Erin Stella Sullivan ,&nbsp;Hannah Furness ,&nbsp;Ione de Brito-Ashurst ,&nbsp;Susanne Cruickshank ,&nbsp;Nicolò Matteo Luca Battisti","doi":"10.1016/j.jgo.2026.102850","DOIUrl":"10.1016/j.jgo.2026.102850","url":null,"abstract":"<div><h3>Introduction</h3><div>Cancer primarily affects older adults, with a significant proportion also experiencing sarcopenia which is associated with poor clinical outcomes. In older adults with cancer, sarcopenia is not only age-related but also exacerbated by disease processes, inflammation, and the catabolic effects of treatments such as chemotherapy and radiotherapy. Its presence is linked to increased treatment toxicity, longer hospitalisations, reduced physical function, and poorer survival rates. However, diagnosing sarcopenia remains challenging due to inconsistent criteria and limited access to diagnostic tools. Emerging evidence suggests that nutritional interventions may help prevent or reverse sarcopenia. This review aims to evaluate the effectiveness of nutritional interventions in managing sarcopenia in older adults with cancer.</div></div><div><h3>Materials and methods</h3><div>A systematic review was conducted using the PICO framework, targeting studies involving patients aged 65 and older with cancer and confirmed or likely sarcopenia. A total of 1439 studies were retrieved from databases and screened using Rayyan. Data extraction focused on outcomes related to body composition, physical performance, and nutritional intake. Risk of bias was assessed using RoB2, ROBINS-I, and ROBINS-E tools. Due to heterogeneity in study designs and outcome measures, a narrative synthesis was performed using SWiM guidelines. Studies were grouped by design and intervention type, and the GRADE approach was applied to assess evidence certainty.</div></div><div><h3>Results</h3><div>Nine studies (2016–2024) met the inclusion criteria. Interventions included dietary supplements, nutritional counselling, enteral feeding, and multimodal strategies. Most studies showed improvements in sarcopenia-related outcomes. Protein supplementation notably improved lean body mass and skeletal muscle index in some randomised control trials (RCTs). Observational studies found associations between certain dietary patterns—such as high fish and fat intake—and reduced sarcopenia risk.</div></div><div><h3>Discussion</h3><div>Nutritional interventions show promise in managing sarcopenia among older adults with cancer. However, further large-scale, standardised research is needed. Meanwhile, promoting good nutrition and physical activity remains essential.</div></div>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"17 2","pages":"Article 102850"},"PeriodicalIF":2.7,"publicationDate":"2026-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146018535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recalibrating the Hester Davis Scale for fall risk in patients with breast cancer 乳腺癌患者跌倒风险的海丝特戴维斯量表的重新校准。
IF 2.7 3区 医学 Q3 GERIATRICS & GERONTOLOGY Pub Date : 2026-01-20 DOI: 10.1016/j.jgo.2026.102856
Asmaa Namoos , Nicholas Thomson , Rana Ramadan , Tamas Gal
{"title":"Recalibrating the Hester Davis Scale for fall risk in patients with breast cancer","authors":"Asmaa Namoos ,&nbsp;Nicholas Thomson ,&nbsp;Rana Ramadan ,&nbsp;Tamas Gal","doi":"10.1016/j.jgo.2026.102856","DOIUrl":"10.1016/j.jgo.2026.102856","url":null,"abstract":"","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"17 2","pages":"Article 102856"},"PeriodicalIF":2.7,"publicationDate":"2026-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146018527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Survival benefit from evidence-based treatment for rectal cancer among older people – Analysis of SEER-medicare 老年人直肠癌循证治疗的生存获益——seer医疗保险分析。
IF 2.7 3区 医学 Q3 GERIATRICS & GERONTOLOGY Pub Date : 2026-01-19 DOI: 10.1016/j.jgo.2026.102851
Uma R. Phatak , Yong Shan , Yong-Fang Kuo

Introduction

The treatment of stage III rectal cancer (RC) is complex and requires a multidisciplinary approach. Evidence-based guidelines (EBG) exist for the treatment of RC. We aimed to determine adherence to EBG in the treatment of stage III RC and the impact on survival in older adults.

Materials and methods

This is a retrospective study of patients within the Surveillance, Epidemiology, and End Results program (SEER). We included adults with stage III RC between 2007 and 2018 with one pathologically confirmed primary tumor. We defined guideline-based care as receipt of: chemoradiation within 6 months of date of diagnosis; surgery within 6 months of completion of chemoradiation; and chemotherapy after surgery. Overall survival (OS) and cancer-specific survival (CSS) were analyzed using the Kaplan-Meier method. Multivariable Cox regression was performed to determine factors associated with survival.

Results

We identified 3962 patients, and 1945 (49.1%) were female. There were 1707 (43.1%) with a Charlson Comorbidity Index of zero. Of the total, 994 (25.1%) received all guideline-based treatments. Factors associated with lack of guideline-based care included age, comorbidities, income, and geographic location. Guideline-based care was associated with increased OS (HR: 0.55, 95% CI: 0.49–0.60) and CSS (HR: 0.59, 95% CI: 0.48–0.73).

Discussion

Although 43.1% of the cohort had a comorbidity index of zero, only 25.1% received all guideline-based treatments. Deviation from guideline-based care had a significant impact on OS. Our data show that more efforts can be made to recommend multimodal RC treatment among older adults.
III期直肠癌(RC)的治疗是复杂的,需要多学科的方法。针对RC的治疗存在循证指南(EBG)。我们的目的是确定EBG治疗III期RC的依从性及其对老年人生存的影响。材料和方法:这是一项对监测、流行病学和最终结果项目(SEER)患者的回顾性研究。我们纳入了2007年至2018年间患有III期RC的成年人,其中有一个病理证实的原发肿瘤。我们将基于指南的治疗定义为:诊断后6个月内接受放化疗;放化疗完成后6个月内手术;还有手术后的化疗。采用Kaplan-Meier法分析总生存期(OS)和肿瘤特异性生存期(CSS)。采用多变量Cox回归确定与生存率相关的因素。结果:3962例患者中女性1945例(49.1%)。Charlson合并症指数为零的1707例(43.1%)。其中,994例(25.1%)接受了所有基于指南的治疗。与缺乏基于指南的护理相关的因素包括年龄、合并症、收入和地理位置。基于指南的护理与OS (HR: 0.55, 95% CI: 0.49-0.60)和CSS (HR: 0.59, 95% CI: 0.48-0.73)的增加相关。讨论:尽管43.1%的队列患者的合并症指数为零,但只有25.1%的患者接受了所有基于指南的治疗。偏离基于指南的护理对OS有显著影响。我们的数据表明,在老年人中推荐多模式RC治疗可以做更多的努力。
{"title":"Survival benefit from evidence-based treatment for rectal cancer among older people – Analysis of SEER-medicare","authors":"Uma R. Phatak ,&nbsp;Yong Shan ,&nbsp;Yong-Fang Kuo","doi":"10.1016/j.jgo.2026.102851","DOIUrl":"10.1016/j.jgo.2026.102851","url":null,"abstract":"<div><h3>Introduction</h3><div>The treatment of stage III rectal cancer (RC) is complex and requires a multidisciplinary approach. Evidence-based guidelines (EBG) exist for the treatment of RC. We aimed to determine adherence to EBG in the treatment of stage III RC and the impact on survival in older adults.</div></div><div><h3>Materials and methods</h3><div>This is a retrospective study of patients within the Surveillance, Epidemiology, and End Results program (SEER). We included adults with stage III RC between 2007 and 2018 with one pathologically confirmed primary tumor. We defined guideline-based care as receipt of: chemoradiation within 6 months of date of diagnosis; surgery within 6 months of completion of chemoradiation; and chemotherapy after surgery. Overall survival (OS) and cancer-specific survival (CSS) were analyzed using the Kaplan-Meier method. Multivariable Cox regression was performed to determine factors associated with survival.</div></div><div><h3>Results</h3><div>We identified 3962 patients, and 1945 (49.1%) were female. There were 1707 (43.1%) with a Charlson Comorbidity Index of zero. Of the total, 994 (25.1%) received all guideline-based treatments. Factors associated with lack of guideline-based care included age, comorbidities, income, and geographic location. Guideline-based care was associated with increased OS (HR: 0.55, 95% CI: 0.49–0.60) and CSS (HR: 0.59, 95% CI: 0.48–0.73).</div></div><div><h3>Discussion</h3><div>Although 43.1% of the cohort had a comorbidity index of zero, only 25.1% received all guideline-based treatments. Deviation from guideline-based care had a significant impact on OS. Our data show that more efforts can be made to recommend multimodal RC treatment among older adults.</div></div>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"17 2","pages":"Article 102851"},"PeriodicalIF":2.7,"publicationDate":"2026-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146010334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oncogeriatric assessment: Expert consensus recommendations in Chile 老年肿瘤评估:智利专家共识建议。
IF 2.7 3区 医学 Q3 GERIATRICS & GERONTOLOGY Pub Date : 2026-01-19 DOI: 10.1016/j.jgo.2026.102847
Rocío Quilodrán Loyola , Gabriel Martínez Fuentes , Isidora Jiménez Álvarez , Evangelina Röling , Gonzalo Navarrete Hernández
{"title":"Oncogeriatric assessment: Expert consensus recommendations in Chile","authors":"Rocío Quilodrán Loyola ,&nbsp;Gabriel Martínez Fuentes ,&nbsp;Isidora Jiménez Álvarez ,&nbsp;Evangelina Röling ,&nbsp;Gonzalo Navarrete Hernández","doi":"10.1016/j.jgo.2026.102847","DOIUrl":"10.1016/j.jgo.2026.102847","url":null,"abstract":"","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"17 2","pages":"Article 102847"},"PeriodicalIF":2.7,"publicationDate":"2026-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146010187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comorbidity cluster trajectories across the care continuum in older women with breast cancer initiating adjuvant endocrine therapy 开始辅助内分泌治疗的老年乳腺癌妇女的共病簇轨迹
IF 2.7 3区 医学 Q3 GERIATRICS & GERONTOLOGY Pub Date : 2026-01-19 DOI: 10.1016/j.jgo.2026.102852
Sola Han , Hyejoong M. Lee , Chanhyun Park

Introduction

With the growing population of older breast cancer survivors, understanding how chronic comorbidities evolve across treatment and toward the end-of-life (EOL) is increasingly important. We aimed to characterize temporal and EOL patterns of comorbidity clusters before and after adjuvant endocrine therapy (AET) among women aged 66–79 years and ≥ 80 years with breast cancer.

Materials and methods

We used the 2016–2019 SEER-Medicare data to identify women aged ≥66 years who initiated AET in 2017. Eligible patients had hormone receptor–positive, stage I–III breast cancer diagnosed within one year prior to AET initiation (index date). Comorbidities were defined using Clinical Classifications Software Refined (CCSR) codes. To identify comorbidity patterns, we applied agglomerative hierarchical clustering using Jaccard's dissimilarity index and Ward's minimum variance method to the top 50 CCSR categories across four periods: pre-index, post–year 1, post–year 2, and EOL.

Results

We identified 11,551 women, of whom 11,050 were alive at the end of follow-up and 501 died during follow-up. Among the patients who were alive, more than 50% had ≥2 chronic conditions across the observation windows. Cardiovascular diseases and their associated risk factors showed the largest increase over time. The most consistent and prevalent cluster across post–year 1, post–year 2, and EOL was “cardiovascular and pulmonary diseases,” including hypertension, coronary atherosclerosis, with additional respiratory and kidney-related conditions emerging near EOL.

Discussion

Comorbidity clustering was common and persisted across observation windows, with cardiovascular and related conditions prominent and expanding near EOL. These patterns highlight the need for integrated cardio-oncology and geriatric co-management to address the complex care needs of older women receiving AET.
随着老年乳腺癌幸存者人数的增加,了解慢性合并症如何在治疗过程中演变并走向生命末期(EOL)变得越来越重要。我们的目的是描述66-79岁和≥80岁的乳腺癌患者在辅助内分泌治疗(AET)前后合并症群的时间和EOL模式。材料和方法:我们使用2016-2019年SEER-Medicare数据来识别2017年开始AET的年龄≥66岁的女性。符合条件的患者在AET开始前一年内诊断为激素受体阳性的I-III期乳腺癌(索引日期)。使用临床分类软件改进(CCSR)代码定义合并症。为了确定共病模式,我们使用Jaccard的不相似指数和Ward的最小方差法对四个时期的前50个CCSR类别进行了聚集层次聚类:指数前、1年后、2年后和EOL。结果:我们确定了11,551名女性,其中11,050名在随访结束时存活,501名在随访期间死亡。在存活的患者中,超过50%的患者在观察期内患有≥2种慢性疾病。随着时间的推移,心血管疾病及其相关风险因素的增加幅度最大。在1年后、2年后和EOL中,最一致和最普遍的一类是“心血管和肺部疾病”,包括高血压、冠状动脉粥样硬化,在EOL附近出现额外的呼吸和肾脏相关疾病。讨论:合并症聚类是常见的,并且在整个观察窗口中持续存在,心血管和相关疾病在EOL附近突出并扩大。这些模式强调需要综合的心脏肿瘤学和老年联合管理,以解决接受AET的老年妇女的复杂护理需求。
{"title":"Comorbidity cluster trajectories across the care continuum in older women with breast cancer initiating adjuvant endocrine therapy","authors":"Sola Han ,&nbsp;Hyejoong M. Lee ,&nbsp;Chanhyun Park","doi":"10.1016/j.jgo.2026.102852","DOIUrl":"10.1016/j.jgo.2026.102852","url":null,"abstract":"<div><h3>Introduction</h3><div>With the growing population of older breast cancer survivors, understanding how chronic comorbidities evolve across treatment and toward the end-of-life (EOL) is increasingly important. We aimed to characterize temporal and EOL patterns of comorbidity clusters before and after adjuvant endocrine therapy (AET) among women aged 66–79 years and ≥ 80 years with breast cancer.</div></div><div><h3>Materials and methods</h3><div>We used the 2016–2019 SEER-Medicare data to identify women aged ≥66 years who initiated AET in 2017. Eligible patients had hormone receptor–positive, stage I–III breast cancer diagnosed within one year prior to AET initiation (index date). Comorbidities were defined using Clinical Classifications Software Refined (CCSR) codes. To identify comorbidity patterns, we applied agglomerative hierarchical clustering using Jaccard's dissimilarity index and Ward's minimum variance method to the top 50 CCSR categories across four periods: pre-index, post–year 1, post–year 2, and EOL.</div></div><div><h3>Results</h3><div>We identified 11,551 women, of whom 11,050 were alive at the end of follow-up and 501 died during follow-up. Among the patients who were alive, more than 50% had ≥2 chronic conditions across the observation windows. Cardiovascular diseases and their associated risk factors showed the largest increase over time. The most consistent and prevalent cluster across post–year 1, post–year 2, and EOL was “cardiovascular and pulmonary diseases,” including hypertension, coronary atherosclerosis, with additional respiratory and kidney-related conditions emerging near EOL.</div></div><div><h3>Discussion</h3><div>Comorbidity clustering was common and persisted across observation windows, with cardiovascular and related conditions prominent and expanding near EOL. These patterns highlight the need for integrated cardio-oncology and geriatric co-management to address the complex care needs of older women receiving AET.</div></div>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"17 2","pages":"Article 102852"},"PeriodicalIF":2.7,"publicationDate":"2026-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146010898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Health-related quality of life among adult cancer patients with and without HIV: Analysis of SEER-MHOS data (2007–2017) 感染和不感染艾滋病毒的成年癌症患者的健康相关生活质量:SEER-MHOS数据分析(2007-2017)
IF 2.7 3区 医学 Q3 GERIATRICS & GERONTOLOGY Pub Date : 2026-01-19 DOI: 10.1016/j.jgo.2026.102855
Yu Chen Lin , Di Kang , Biwei Cao , Emma Hume , Amir Alishahi Tabriz , Gita Suneja , Anna E. Coghill , Heather Jim , Kea Turner , Jessica Y. Islam

Introduction

People with HIV (PWH) are more likely to die due to cancer compared to people without HIV. Disparities in cancer care, including access to palliative care, for PWH contribute to poor health-related quality of life (HRQoL) and survival. However, limited research exists examining patient-reported HRQoL among PWH with cancer. We examined HRQoL among patients diagnosed with non-AIDS defining cancers with and without HIV.

Materials and methods

We used the 2007–2017 Surveillance, Epidemiology, and End Results and the Medicare Health Outcomes Survey (SEER-MHOS) linkage data to assess HRQoL among patients (ages ≥18) diagnosed with breast, colorectal, gastrointestinal, head and neck, lung, lymphoma, and prostate cancers. HRQoL outcomes included the Physical Component Summary (PCS) and Mental Component Summary (MCS) scores and the eight scale scores of the Veterans RAND 12-Item Health Survey (VR-12), and the VR-6D health utility score. Higher HRQoL scores indicate better health status. Adjusting for patient characteristics, we computed mean HRQoL scores using multivariable linear regression models and the predictive margins method. The minimally important difference (MID) in HRQoL scores between patients with and without HIV by cancer types was assessed.

Results

The sample (N = 43,973) included 310 (0.7%) patients with HIV and had an average age at cancer diagnosis of 70.8 years. PWH reported lower scores in at least one HRQoL outcome compared to patients without HIV for all cancers examined. Differences in HRQoL for PWH compared to patients without HIV exceeded the MID for cancers of the breast (PCS: -2.7; MCS: -9.1; VR-6D: −0.08), colorectum (PCS: -2.3; MCS: -6.2; VR-6D: −0.06), gastrointestinal tract (MCS: -5.9; VR-6D: −0.04), head and neck (PCS: -4.1; MCS: -7.5; VR-6D: −0.07), lungs (PCS: -2.5; MCS: -6.3; VR-6D: −0.06), lymphatic system (PCS: -2.3; MCS: -2.6; VR-6D: −0.04), and prostate (MCS: -8.0; VR-6D: −0.07).

Discussion

Our findings demonstrated that PWH across all cancers examined reported substantially lower mental and/or physical HRQoL compared to patients without HIV. Future work can explore strategies for symptom monitoring and management among PWH.
与未感染艾滋病毒的人相比,感染艾滋病毒的人更有可能死于癌症。癌症治疗方面的差异,包括获得姑息治疗的机会,导致与健康相关的生活质量(HRQoL)和生存率差。然而,对患有癌症的PWH患者报告的HRQoL的研究有限。我们检查了被诊断为非艾滋病的患者的HRQoL,定义了有和没有艾滋病毒的癌症。材料和方法:我们使用2007-2017年监测、流行病学和最终结果以及医疗保险健康结局调查(SEER-MHOS)的关联数据来评估诊断为乳腺癌、结直肠癌、胃肠癌、头颈癌、肺癌、淋巴瘤和前列腺癌的患者(年龄≥18岁)的HRQoL。HRQoL结果包括身体成分总结(PCS)和心理成分总结(MCS)得分、退伍军人RAND 12项健康调查(VR-12)的8个量表得分和VR-6D健康效用得分。HRQoL评分越高,说明健康状况越好。调整患者特征后,我们使用多变量线性回归模型和预测边际法计算平均HRQoL评分。评估不同癌症类型HIV感染者和非HIV感染者HRQoL评分的最小重要差异(MID)。结果:样本(N = 43,973)包括310例(0.7%)HIV患者,癌症诊断时的平均年龄为70.8岁。与未感染艾滋病毒的所有癌症患者相比,PWH患者在至少一项HRQoL结果中得分较低。与未感染HIV的患者相比,PWH患者HRQoL的差异超过了乳腺癌(PCS: -2.7; MCS: -9.1; VR-6D: -0.08)、结直肠癌(PCS: -2.3; MCS: -6.2; VR-6D: -0.06)、胃肠道(MCS: -5.9; VR-6D: -0.04)、头颈部(PCS: -4.1; MCS: -7.5; VR-6D: -0.07)、肺部(PCS: -2.5; MCS: -6.3; VR-6D: -0.06)、淋巴系统(PCS: -2.3; MCS: -2.6; VR-6D: -0.04)和前列腺(MCS: -8.0; VR-6D: -0.07)等癌症的MID。讨论:我们的研究结果表明,与未感染艾滋病毒的患者相比,所有癌症的PWH患者报告的精神和/或身体HRQoL明显较低。未来的工作可以探索PWH症状监测和管理的策略。
{"title":"Health-related quality of life among adult cancer patients with and without HIV: Analysis of SEER-MHOS data (2007–2017)","authors":"Yu Chen Lin ,&nbsp;Di Kang ,&nbsp;Biwei Cao ,&nbsp;Emma Hume ,&nbsp;Amir Alishahi Tabriz ,&nbsp;Gita Suneja ,&nbsp;Anna E. Coghill ,&nbsp;Heather Jim ,&nbsp;Kea Turner ,&nbsp;Jessica Y. Islam","doi":"10.1016/j.jgo.2026.102855","DOIUrl":"10.1016/j.jgo.2026.102855","url":null,"abstract":"<div><h3>Introduction</h3><div>People with HIV (PWH) are more likely to die due to cancer compared to people without HIV. Disparities in cancer care, including access to palliative care, for PWH contribute to poor health-related quality of life (HRQoL) and survival. However, limited research exists examining patient-reported HRQoL among PWH with cancer. We examined HRQoL among patients diagnosed with non-AIDS defining cancers with and without HIV.</div></div><div><h3>Materials and methods</h3><div>We used the 2007–2017 Surveillance, Epidemiology, and End Results and the Medicare Health Outcomes Survey (SEER-MHOS) linkage data to assess HRQoL among patients (ages ≥18) diagnosed with breast, colorectal, gastrointestinal, head and neck, lung, lymphoma, and prostate cancers. HRQoL outcomes included the Physical Component Summary (PCS) and Mental Component Summary (MCS) scores and the eight scale scores of the Veterans RAND 12-Item Health Survey (VR-12), and the VR-6D health utility score. Higher HRQoL scores indicate better health status. Adjusting for patient characteristics, we computed mean HRQoL scores using multivariable linear regression models and the predictive margins method. The minimally important difference (MID) in HRQoL scores between patients with and without HIV by cancer types was assessed.</div></div><div><h3>Results</h3><div>The sample (<em>N</em> = 43,973) included 310 (0.7%) patients with HIV and had an average age at cancer diagnosis of 70.8 years. PWH reported lower scores in at least one HRQoL outcome compared to patients without HIV for all cancers examined. Differences in HRQoL for PWH compared to patients without HIV exceeded the MID for cancers of the breast (PCS: -2.7; MCS: -9.1; VR-6D: −0.08), colorectum (PCS: -2.3; MCS: -6.2; VR-6D: −0.06), gastrointestinal tract (MCS: -5.9; VR-6D: −0.04), head and neck (PCS: -4.1; MCS: -7.5; VR-6D: −0.07), lungs (PCS: -2.5; MCS: -6.3; VR-6D: −0.06), lymphatic system (PCS: -2.3; MCS: -2.6; VR-6D: −0.04), and prostate (MCS: -8.0; VR-6D: −0.07).</div></div><div><h3>Discussion</h3><div>Our findings demonstrated that PWH across all cancers examined reported substantially lower mental and/or physical HRQoL compared to patients without HIV. Future work can explore strategies for symptom monitoring and management among PWH.</div></div>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"17 2","pages":"Article 102855"},"PeriodicalIF":2.7,"publicationDate":"2026-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146010179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Quality cancer care for older adults from culturally and linguistically diverse backgrounds: Perspectives from the Cancer and Aging Research Group Junior Board 来自不同文化和语言背景的老年人的高质量癌症护理:来自癌症和老龄化研究小组初级委员会的观点。
IF 2.7 3区 医学 Q3 GERIATRICS & GERONTOLOGY Pub Date : 2026-01-19 DOI: 10.1016/j.jgo.2026.102853
Surbhi Singhal , Maya Abdallah , Tanyanika Phillips , Nicole A. Arrato , Mukul Roy , Samantha Werts-Pelter , Katherine Ramos , Chad Yixian Han
{"title":"Quality cancer care for older adults from culturally and linguistically diverse backgrounds: Perspectives from the Cancer and Aging Research Group Junior Board","authors":"Surbhi Singhal ,&nbsp;Maya Abdallah ,&nbsp;Tanyanika Phillips ,&nbsp;Nicole A. Arrato ,&nbsp;Mukul Roy ,&nbsp;Samantha Werts-Pelter ,&nbsp;Katherine Ramos ,&nbsp;Chad Yixian Han","doi":"10.1016/j.jgo.2026.102853","DOIUrl":"10.1016/j.jgo.2026.102853","url":null,"abstract":"","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"17 2","pages":"Article 102853"},"PeriodicalIF":2.7,"publicationDate":"2026-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146010374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of geriatric oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1